• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液疾病患者输血支持中新鲜冰冻血浆、冷沉淀、免疫球蛋白和凝血因子应用的最新进展。

Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease.

机构信息

United States Army Institute of Surgical Research, JBSA Fort Sam Houston, TX, USA.

San Antonio Military Medical Center, JBSA Fort Sam Houston, TX, USA.

出版信息

Semin Hematol. 2020 Apr;57(2):73-82. doi: 10.1053/j.seminhematol.2020.07.006. Epub 2020 Jul 27.

DOI:10.1053/j.seminhematol.2020.07.006
PMID:32892846
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7384412/
Abstract

Hematologic diseases include a broad range of acquired and congenital disorders, many of which affect plasma proteins that control hemostasis and immune responses. Therapeutic interventions for these disorders include transfusion of plasma, cryoprecipitate, immunoglobulins, or convalescent plasma-containing therapeutic antibodies from patients recovering from infectious diseases, as well as concentrated pro- or anticoagulant factors. This review will focus on recent advances in the uses of plasma and its derivatives for patients with acquired and congenital hematologic disorders.

摘要

血液系统疾病包括广泛的获得性和先天性疾病,其中许多疾病会影响控制止血和免疫反应的血浆蛋白。这些疾病的治疗干预措施包括输注来自传染病康复患者的血浆、冷沉淀、免疫球蛋白或含有恢复期抗体的康复期血浆,以及浓缩的促凝或抗凝因子。本综述将重点介绍血浆及其衍生物在治疗获得性和先天性血液系统疾病患者方面的最新进展。

相似文献

1
Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease.血液疾病患者输血支持中新鲜冰冻血浆、冷沉淀、免疫球蛋白和凝血因子应用的最新进展。
Semin Hematol. 2020 Apr;57(2):73-82. doi: 10.1053/j.seminhematol.2020.07.006. Epub 2020 Jul 27.
2
Hemostatic characteristics of thawed, pooled cryoprecipitate stored for 35 days at refrigerated and room temperatures.在冷藏和室温下储存35天的解冻混合冷沉淀的止血特性。
Transfusion. 2019 Apr;59(S2):1560-1567. doi: 10.1111/trf.15180.
3
Coagulation, hemostasis, and transfusion during liver transplantation.肝移植期间的凝血、止血和输血。
Best Pract Res Clin Anaesthesiol. 2020 Mar;34(1):79-87. doi: 10.1016/j.bpa.2020.03.002. Epub 2020 Mar 16.
4
Thawed plasma an alternative to fresh frozen plasma.解冻血浆可替代新鲜冰冻血浆。
J Trauma Nurs. 2005 Apr-Jun;12(2):57-8. doi: 10.1097/00043860-200512020-00007.
5
Comparison of albumin, colloid osmotic pressure, von Willebrand factor, and coagulation factors in canine cryopoor plasma, cryoprecipitate, and fresh frozen plasma.犬贫冷沉淀血浆、冷沉淀和新鲜冰冻血浆中白蛋白、胶体渗透压、血管性血友病因子及凝血因子的比较。
J Vet Emerg Crit Care (San Antonio). 2017 Nov;27(6):638-644. doi: 10.1111/vec.12671. Epub 2017 Oct 24.
6
Stability of coagulation factors in plasma prepared after a 24-hour room temperature hold.室温放置 24 小时后制备的血浆中凝血因子的稳定性。
Transfusion. 2010 Sep;50(9):1934-42. doi: 10.1111/j.1537-2995.2010.02648.x.
7
The role of cryoprecipitate in human and canine transfusion medicine.冷沉淀在人类和犬类输血医学中的作用。
J Vet Emerg Crit Care (San Antonio). 2021 Mar;31(2):204-214. doi: 10.1111/vec.13034. Epub 2021 Mar 10.
8
[Indications for blood transfusion].[输血指征]
Gematol Transfuziol. 1989 Aug;34(8):47-53.
9
Clotting factors in cryoprecipitate and cryo-supernatant prepared from MB-treated fresh plasma.用亚甲蓝处理的新鲜血浆制备的冷沉淀和冷上清液中的凝血因子。
Transfusion. 2000 Apr;40(4):493. doi: 10.1046/j.1537-2995.2000.40040493.x.
10
[Patient blood management and transfusion therapy for hemostasis].[患者血液管理与用于止血的输血治疗]
Rinsho Ketsueki. 2017;58(10):2141-2149. doi: 10.11406/rinketsu.58.2141.

引用本文的文献

1
Comparison of Hemostatic Activity in Canine Leukoreduced Cryoprecipitate, Cryopoor Plasma, and Fresh Plasma.犬去白细胞冷沉淀、少冷沉淀血浆和新鲜血浆止血活性的比较。
Vet Clin Pathol. 2025 Jun;54(2):120-131. doi: 10.1111/vcp.70017. Epub 2025 Jun 16.
2
High-dimensional analysis of injured patients reveals distinct circulating proteomic profiles in plasma vs. whole blood resuscitation.对受伤患者的高维分析揭示了血浆复苏与全血复苏中不同的循环蛋白质组学特征。
Cell Rep Med. 2025 Mar 18;6(3):102022. doi: 10.1016/j.xcrm.2025.102022.
3
Antithrombin Therapy: Current State and Future Outlook.抗凝血酶治疗:现状与未来展望。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231205279. doi: 10.1177/10760296231205279.
4
Perioperative Management of Spontaneous Intracranial Hemorrhage in a Patient With Hemophilia A in a Resource Limited Country.资源有限国家中一名甲型血友病患者自发性颅内出血的围手术期管理
Cureus. 2023 Aug 14;15(8):e43485. doi: 10.7759/cureus.43485. eCollection 2023 Aug.
5
Use of Cryoprecipitate in Newborn Infants.冷沉淀在新生儿中的应用。
Newborn (Clarksville). 2023 Jan-Mar;2(1):11-18. doi: 10.5005/jp-journals-11002-0045. Epub 2023 Apr 6.
6
Trends of Blood Transfusion According to Diseases in Korea: A 10-Year Nationwide Cohort Study.韩国按疾病分类的输血趋势:一项为期10年的全国队列研究。
Transfus Med Hemother. 2022 Nov 22;50(2):135-143. doi: 10.1159/000526626. eCollection 2023 Apr.
7
Diffuse alveolar hemorrhage; An under-diagnosed and rare complication of glycoprotein IIb/IIIa inhibitors.弥漫性肺泡出血;糖蛋白IIb/IIIa抑制剂一种诊断不足的罕见并发症。
J Cardiovasc Thorac Res. 2022;14(3):201-204. doi: 10.34172/jcvtr.2022.17. Epub 2022 Jun 25.
8
Use of Fresh-frozen Plasma in Newborn Infants.新鲜冰冻血浆在新生儿中的应用。
Newborn (Clarksville). 2022 Jul-Sep;1(3):271-277. doi: 10.5005/jp-journals-11002-0039. Epub 2022 Jul 10.
9
WBC Image Segmentation Based on Residual Networks and Attentional Mechanisms.基于残差网络和注意力机制的白细胞图像分割。
Comput Intell Neurosci. 2022 Aug 31;2022:1610658. doi: 10.1155/2022/1610658. eCollection 2022.
10
Blood transfusion trends in the United States: national inpatient sample, 2015 to 2018.美国的输血趋势:2015 年至 2018 年全国住院患者样本。
Blood Adv. 2021 Oct 26;5(20):4179-4184. doi: 10.1182/bloodadvances.2021005361.

本文引用的文献

1
In-vitro assessment of the effects of fibrinogen, recombinant factor VIIa and factor XIII on trauma-induced coagulopathy.体外评估纤维蛋白原、重组因子 VIIa 和因子 XIII 对创伤诱导性凝血病的影响。
Blood Coagul Fibrinolysis. 2020 Jun;31(4):253-257. doi: 10.1097/MBC.0000000000000910.
2
A Case of Acquired Factor V Deficiency in Patient with Bleeding.一例出血患者获得性因子V缺乏症病例
TH Open. 2020 Apr 20;4(2):e77-e79. doi: 10.1055/s-0039-3402024. eCollection 2020 Apr.
3
Protein S Deficiency and Arterial Thromboembolism: A Case Report and Review of the Literature.蛋白S缺乏与动脉血栓栓塞:一例病例报告及文献综述
J Hematol. 2019 Mar;8(1):37-39. doi: 10.14740/jh478. Epub 2019 Mar 30.
4
Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.中国武汉 COVID-19 患者恢复期血浆治疗。
J Med Virol. 2020 Oct;92(10):1890-1901. doi: 10.1002/jmv.25882. Epub 2020 Jun 29.
5
Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea.韩国两名急性呼吸窘迫综合征 COVID-19 患者使用恢复期血浆疗法。
J Korean Med Sci. 2020 Apr 13;35(14):e149. doi: 10.3346/jkms.2020.35.e149.
6
Clot Formation in Cardiopulmonary Bypass Circuit After Application of Factor XI Concentrate.应用凝血因子 XI 浓缩物后体外循环回路中的血栓形成。
J Cardiothorac Vasc Anesth. 2020 Aug;34(8):2178-2180. doi: 10.1053/j.jvca.2020.02.013. Epub 2020 Feb 12.
7
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.恢复期血浆疗法治疗重症 COVID-19 患者的疗效。
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
8
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
9
Ischemic Stroke with Protein S Deficiency Treated by Apixaban.蛋白 S 缺乏症所致缺血性脑卒中的阿哌沙班治疗。
J Stroke Cerebrovasc Dis. 2020 Apr;29(4):104608. doi: 10.1016/j.jstrokecerebrovasdis.2019.104608. Epub 2020 Jan 13.
10
Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy.用于预防遗传性血管性水肿(HAE)的注射用拉那度单抗:设计、研发及治疗地位
Drug Des Devel Ther. 2019 Oct 22;13:3635-3646. doi: 10.2147/DDDT.S192475. eCollection 2019.